Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 18, 2021 | May 20, 2021 |
| Rivian Automotive, Inc. / DERIVN · Entity 3226 | Director | June 22, 2026 | June 23, 2026 |
| Senti Biosciences Holdings, Inc.DYNS · Entity 7935 | Director | May 25, 2021 | May 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,628 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 22,628 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 336,313 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 336,313 F3: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee.
F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
ILLUMINA, INC.
Report date May 18, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,933 |
Reported balance
After 2021-05-18 transaction · row 1
1 source rowRow 1 · 2021-05-18 · Sale · Disposed 4,000 · Balance 148,933 F1: The sale was made pursuant to a 10b5-1 plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Daughters | 3,500 |
Reported balance
Holding disclosure · report date 2021-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was made pursuant to a 10b5-1 plan.
Rivian Automotive, Inc. / DE
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 179,515 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 17,445 · Balance 179,515 F1: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 17,445 restricted stock units ("RSUs") which will vest on the first anniversary of the grant date.
Senti Biosciences Holdings, Inc.
Report date May 25, 2021 · Filed May 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | IndirectSee footnote | 10,733 |
Reported balance
Holding disclosure · report date 2021-05-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,733 F1: Up to 900 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus"). F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers. |
| Class B common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2021-05-25 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date. F4: Up to 4,894 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus. F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers. |
Filing footnotes · ownership attribution and instrument terms
F1: Up to 900 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus").
F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. Any action by the Sponsor with respect to Issuer or the shares reported above, including voting and dispositive decisions, requires unanimous approval of the managers.
F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date.
F4: Up to 4,894 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COHERENT INC
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 43,018 · Balance 0 F1: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: On July 1, 2022, II-VI Incorporated ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Watson Merger Sub Inc, a direct, wholly owned subsidiary of Buyer ("Merger Sub"), dated as of March 25, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $220.00 in cash, without interest (the "Cash Consideration"), plus 0.91 of a validly issued, fully paid and nonassessable share of Buyer (the "Merger Consideration").
Juno Therapeutics, Inc.
Report date March 05, 2018 · Filed March 07, 2018
Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Flatley Family Trust | 0 |
Reported balance
After 2018-03-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-03-05 · Other · Disposed 31,500 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2027-05-21 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-05 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2027-06-15 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
F3: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
Zymergen Inc.
Report date October 19, 2022 · Filed October 20, 2022
Section 16 reporting ended · disclosed 2022-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 1
1 source rowRow 1 · 2022-10-19 · Disposition to issuer · Disposed 144,789 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.33 · Expires 2031-08-06 | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-19 · Disposition to issuer · Disposed 1,520,000 · Balance 0 F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.52 · Expires 2029-09-17 | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-19 · Disposition to issuer · Disposed 189,125 · Balance 0 F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo.
F2: Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2019 Filed Feb 14, 2019 21:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 28,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005997 · form4.xml · derivative · entry 6 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,888 shares Expires 2018-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 16,828 | $292.20 | $4,917,141.60 |
DisclosureSEC source: 0001127602-19-005997 · form4.xml · nonDerivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,168 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 6,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005997 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,996 F2 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 121% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 28,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005997 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 8, 2015. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:27 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $303.53 | $1,001,649.00 |
DisclosureSEC source: 0001127602-19-002736 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,979 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 21:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $296.20 | $977,460.00 |
DisclosureSEC source: 0001127602-19-001879 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,279 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 22:36 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $273.87 | $903,771.00 |
DisclosureSEC source: 0001127602-18-037498 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,579 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 00:26 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $334.13 | $1,102,629.00 |
DisclosureSEC source: 0001127602-18-036248 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,559 F2 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 12, 2018 Filed Dec 28, 2018 22:36 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GiftCommon Stock | 31,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-037498 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,879 Read SEC document |
| December 11, 2018 Filed Dec 14, 2018 00:26 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 6,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036248 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,859 F1 · shares: Grant of restricted stock units shall vest as follows: 100% of the shares subject to the award shall vest on December 11, 2019 subject to awardee's continuing status as a service provider on such date. Read SEC document |
| December 11, 2018 Filed Dec 14, 2018 00:19 UTC Amendment | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 4,632 | $328.90 | $1,523,464.80 |
DisclosureSEC source: 0001110803-18-000034 · primary_doc.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,778 F1 · date: This Form is being filed to correct the vest date and the applicable price. F1 · price: This Form is being filed to correct the vest date and the applicable price. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:14 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 4,632 | $334.32 | $1,548,570.24 |
DisclosureSEC source: 0001127602-18-035576 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,778 Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 21:24 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $321.80 | $1,061,940.00 |
DisclosureSEC source: 0001127602-18-034843 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,410 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 21:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $312.50 | $1,031,250.00 |
DisclosureSEC source: 0001127602-18-033404 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,710 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 2,337 | $324.14 | $757,515.18 |
DisclosureSEC source: 0001127602-18-032442 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,010 F1 · balance_after: Balance includes 43 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 20:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $310.58 | $1,024,914.00 |
DisclosureSEC source: 0001127602-18-031057 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,304 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 20:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $321.58 | $1,061,214.00 |
DisclosureSEC source: 0001127602-18-030073 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,604 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| September 26, 2018 Filed Sep 28, 2018 21:29 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $360.81 | $1,190,673.00 |
DisclosureSEC source: 0001127602-18-028588 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,904 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| September 12, 2018 Filed Sep 15, 2018 01:25 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,300 | $351.66 | $1,160,478.00 |
DisclosureSEC source: 0001127602-18-027639 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,204 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 22:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001209191-18-038157 · doc4.xml · derivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,830 Underlying: Common Stock · 27,830 shares Expires 2028-06-12 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| May 14, 2018 Filed May 17, 2018 01:40 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,460 | $268.00 | $391,280.00 |
DisclosureSEC source: 0001127602-18-017796 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughters Disclosed balance after: 4,000 F1 · balance_after: Reflects transfer of 5,320 shares from direct to indirect ownership prior to sale. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:19 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $63.71 Strike: $23.29 | $764,520.00 |
DisclosureSEC source: 0001209191-18-017810 · doc4.xml · derivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-15 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F3 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:19 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 18,000 | $62.93 Strike: $24.07 | $1,132,740.00 |
DisclosureSEC source: 0001209191-18-017810 · doc4.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2027-05-21 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F3 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:19 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | OtherCommon Stock | 31,500 | $87.00 | $2,740,500.00 |
DisclosureSEC source: 0001209191-18-017810 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Flatley Family Trust Disclosed balance after: 0 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · date: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:51 UTC | COHERENT INC COHR · Entity 125737 | GrantCommon Stock | 916 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003453 · edgar.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916 F1 · shares: On March 1, 2018 the Reporting Person was granted 916 Restricted Stock Units which will vest on February 15, 2019. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:07 UTC | COHERENT INC COHR · Entity 125737 | Exercise / conversionRestricted Stock Units · Derivative | 1,293 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002287 · edgar.xml · derivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,293 shares Expires 2018-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:07 UTC | COHERENT INC COHR · Entity 125737 | Exercise / conversionCommon Stock | 1,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002287 · edgar.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Family Trust Disclosed balance after: 13,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Released shares issued to family trust. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 02:13 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 26,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007406 · form4.xml · derivative · entry 4 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,542 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represented a contingent right to receive a share of Illumina common stock based upon the Company's achievement of certain earnings per share targets as of the three-year period ended December 31, 2017. F1 · shares: Each performance stock unit represented a contingent right to receive a share of Illumina common stock based upon the Company's achievement of certain earnings per share targets as of the three-year period ended December 31, 2017. F1 · derivative.exercise_date: Each performance stock unit represented a contingent right to receive a share of Illumina common stock based upon the Company's achievement of certain earnings per share targets as of the three-year period ended December 31, 2017. F3 · balance_after: 1,105 performance stock units expired not having vested. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 02:13 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 12,882 | $229.13 | $2,951,652.66 |
DisclosureSEC source: 0001127602-18-007406 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,824 F2 · balance_after: Balance includes 102 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 02:13 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 26,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007406 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each performance stock unit represented a contingent right to receive a share of Illumina common stock based upon the Company's achievement of certain earnings per share targets as of the three-year period ended December 31, 2017. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 01:53 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 837 | $241.18 | $201,867.66 |
DisclosureSEC source: 0001127602-18-003066 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,062 Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 700 | $248.37 | $173,861.03 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 7 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,899 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F8 · price: Weighted average sale price representing 700 shares sold ranging from $247.94 to $248.77 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,600 | $247.17 | $395,476.00 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 6 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,599 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F7 · price: Weighted average sale price representing 1,600 shares sold ranging from $246.80 to $247.64 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 702 | $246.37 | $172,948.23 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 5 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,199 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F6 · price: Weighted average sale price representing 702 shares sold ranging from $245.75 to $246.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,400 | $244.72 | $587,335.92 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 4 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,901 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 2,400 shares sold ranging from $244.43 to $245.30 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,300 | $243.56 | $316,622.02 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,301 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 1,300 shares sold ranging from $243.25 to $244.16 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,600 | $242.56 | $1,115,756.22 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,601 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 4,600 shares sold ranging from $242.11 to $243.07 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 3,698 | $241.69 | $893,763.33 |
DisclosureSEC source: 0001127602-18-002124 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,201 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 3,698 shares sold ranging from $241.08 to $242.06 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 02:16 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 10,537 | $223.80 | $2,358,130.02 |
DisclosureSEC source: 0001127602-18-000910 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,899 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 10,537 shares sold ranging from $223.40 to $224.37 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 02:16 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 9,463 | $222.97 | $2,109,960.38 |
DisclosureSEC source: 0001127602-18-000910 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,436 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 9,463 shares sold ranging from $222.37 to $223.35 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 19, 2017 Filed Dec 22, 2017 01:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 2,977 | $216.94 | $645,819.66 |
DisclosureSEC source: 0001127602-17-035393 · form4.xml · nonDerivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,899 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 2,977 shares sold ranging from $216.67 to $217.45 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 19, 2017 Filed Dec 22, 2017 01:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 4,600 | $216.22 | $994,617.06 |
DisclosureSEC source: 0001127602-17-035393 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,876 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 4,600 shares sold ranging from $215.62 to $216.59 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 19, 2017 Filed Dec 22, 2017 01:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 12,423 | $214.85 | $2,669,065.40 |
DisclosureSEC source: 0001127602-17-035393 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,476 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 12,423 shares sold ranging from $214.55 to $215.36 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:39 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065245 · doc4.xml · derivative · entry 3 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:39 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065245 · doc4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 250,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 11, 2017 Filed Dec 14, 2017 01:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 9,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-034612 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,899 F1 · shares: Grant of restricted stock units shall vest as follows: 100% of the shares subject to the award shall vest on December 11, 2018, subject to awardee's continuing status as a service provider on such date. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:55 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 47,165 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-17-064805 · doc4.xml · derivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Underlying: Common Stock · 47,165 shares Expires 2027-12-06 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 05, 2017 Filed Dec 8, 2017 01:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 8,159 | $211.06 | $1,722,038.54 |
DisclosureSEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 7 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,558 Read SEC document |
| December 05, 2017 Filed Dec 8, 2017 01:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 200 | $215.65 | $43,129.00 |
DisclosureSEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 6 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,717 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F7 · price: Weighted average sale price representing 200 shares sold ranging from $215.62 to $215.67 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 05, 2017 Filed Dec 8, 2017 01:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,300 | $214.71 | $279,118.06 |
DisclosureSEC source: 0001127602-17-034165 · form4.xml · nonDerivative · entry 5 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,917 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F6 · price: Weighted average sale price representing 1,300 shares sold ranging from $214.52 to $215.29 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.